CHF Solutions Doubles Production Staff of Aquadex SmartFlow™ Consoles Due to Hospital Demand
April 02 2020 - 8:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload,
announced that it has doubled the production staff that builds its
next generation Aquadex SmartFlow consoles in response to increased
demand from hospitals due to the coronavirus COVID-19.
Following last week’s announcement regarding use of the Aquadex
system in the treatment of critically ill patients, CHF Solutions
has seen strong interest from additional hospitals and increased
demand for this ultrafiltration therapy as the rate of affected
patients continues to increase.
“It is important for medical teams to quickly be aware of all of
the tools available to treat these critically ill patients and have
sufficient supply of life-saving devices,” said John Erb, CEO of
CHF Solutions. “We have hired and trained more production builders
at our manufacturing facility in Minnesota to ensure that
physicians, nurses and the clinical staff have the solutions they
need to treat patients impacted with COVID-19.”
The World Health Organization (WHO) recently released
a protocol for treating patients infected with COVID-19,
highlighting the need for effective fluid management treatment
strategies when caring for the critical patient population because
the risk of volume overload is very high.1 The Aquadex
SmartFlow system is an efficient way of rapidly removing excess
fluid from patients being treated with fluid resuscitation as part
of the treatment for COVID-19.
About CHF Solutions CHF Solutions, Inc.
(Nasdaq: CHFS) is a medical device company dedicated to improving
the lives of patients suffering from fluid overload with its novel
ultrafiltration therapy system. The company is focused on
developing, manufacturing and commercializing the Aquadex SmartFlow
system for ultrafiltration therapy. CHF Solutions is headquartered
in Minneapolis, Minn., with wholly-owned subsidiaries in Australia
and Ireland. The company has been listed on the Nasdaq Capital
Market since February 2012.
About the Aquadex SmartFlow System The Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex SmartFlow
system is indicated for temporary (up to 8 hours) or extended
(longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg or more whose fluid
overload is unresponsive to medical management, including
diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting, under
physician prescription, both having received training in
extracorporeal therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements about the clinical
use of the Aquadex SmartFlow system in patients infected with
COVID-19. Forward-looking statements are predictions, projections
and other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
1 WHO reference number: WHO/nCoV/Clinical/2020.3
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Brad Perriello
Health+Commerce
617-817-1385
brad@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024